Table 1. Patient and treatment characteristics.
| Full cohort (N=59) | Low Aurora CN ⩽2.6 (N=18) | High Aurora CN >2.6 (N=41) | P-value | |
|---|---|---|---|---|
| Age, mean (s.d.) | 58.6 (1.44) | 58.6 (3.2) | 58.7 (1.58) | 0.97 |
| Gender, N (%) | 0.68 | |||
| Male | 37 (62.7) | 12 (66.7) | 25 (61.0) | |
| Female | 22 (37.3) | 6 (33.3) | 16 (39.0) | |
| Race, N (%) | ||||
| Caucasian | 51 (87.9) | 14 (82.3) | 37 (90.2) | 0.41 |
| AA | 7 (12.1) | 3 (17.7) | 4 (9.8) | |
| Stage at diagnosis, N (%) | 0.80 | |||
| 2 | 1 (1.9) | 0 (0) | 1 (2.7) | |
| 3 | 10 (8.9) | 3 (18.8) | 7 (18.9) | |
| 4 | 42 (79.3) | 13 (81.2) | 29 (78.4) | |
| Clinical and treatment data for 53 patients n(%) | ||||
| (N=53) | (N=16) | (N=37) | ||
| No. of metastatic sites | ||||
| 1 | 30 (56.7) | 11 (51.4) | 19 (68.8) | 0.28 |
| 2 | 20 (37.7) | 16 (43.25) | 4 (25.0) | |
| 3 | 2 (3.8) | 1 (2.7) | 1 (6.25) | |
| 4 | 1 (1.8) | 1 (2.7) | 0 (0.0) | |
| First-line therapy (all patients received 5-FU or capecitabine with initial therapy) | ||||
| Oxaliplatin, N (%) | 45 (84.9) | 11 (81.3) | 34 (86.5) | 0.63 |
| Irinotecan, N (%) | 5 (9.4) | 2 (12.5) | 3 (8.1) | 0.63 |
| Cetuximab, N (%) | 19 (35.9) | 7 (43.8) | 12 (32.4) | 0.54 |
| Bevacizumab, N (%) | 35 (66.0) | 10 (62.5) | 25 (67.6) | 0.76 |
| Bevacizumb+Cetuximab, N (%) | 8 (15.0) | 4 (25) | 4 (10.8) | 0.19 |
| Second-line therapy | ||||
| (N=33) | (N=11) | (N=22) | ||
| 5-FU or Capecitabine, N (%) | 14 (42.4) | 7 (63.6) | 7 (31.8) | 0.14 |
| Irinotecan, N (%) | 26 (78.7) | 9 (81.8) | 17 (77.3) | 0.57 |
| Oxaliplatin, N (%) | 2 (6) | 1 (9) | 1 (4.5) | 0.56 |
| Bevacizumab, N (%) | 11 (33.3) | 8 (72.7) | 3 (13.6) | 0.001 |
| Cetuximab/Panitumumab, N (%) | 17 (51.5) | 6 (54.5) | 11 (50) | 0.55 |
| Third-line therapy | 9 (27.2) | 2 (18.2) | 7 (31.8) | 0.35 |
Abbreviations: AA=African American; CN=copy number.